A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
OBJECTIVE
To estimate the antitumor efficacy of CI-958 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of CI-958 in these patients.


METHODS
Patients received CI-958 560 mg/m2 intravenously every 3 weeks and tumor measurements were performed every one to two cycles.


RESULTS
Of 23 patients entered in the study, there was one complete response and 10 patients had stable disease with short response durations.


CONCLUSIONS
CI-958 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested.
Hoffman
M A
MA
Division of Hematology-Oncology, Long Island Jewish Medical Center, Campus of the Albert Einstein College of Medicine, New Hyde Park, New York 11040, USA. hoffman@lij.edu
Blessing
J A
JA
Nuñez
E R
ER
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007191:Indazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D007191:Indazoles; D009944:Organoplatinum Compounds; C054558:ledoxantrone